Loading clinical trials...
Loading clinical trials...
A Phase Ib, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas
Conditions
Interventions
MIW815
PDR001
Locations
12
United States
The Angeles Clinic and Research Institute
Los Angeles, California, United States
Novartis Investigative Site
Chicago, Illinois, United States
MD Anderson Cancer Center
Houston, Texas, United States
Seattle Cancer Care Alliance
Seattle, Washington, United States
Novartis Investigative Site
North Sydney, New South Wales, Australia
Novartis Investigative Site
Melbourne, Victoria, Australia
Start Date
September 8, 2017
Primary Completion Date
December 18, 2020
Completion Date
December 18, 2020
Last Updated
May 3, 2022
NCT02392611
NCT00457574
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions